Single-cell profiling reveals the heterogeneity of NK cells during anti-PD-1 therapy in non-small-cell lung cancer.

[1]  L. Di Marcotullio,et al.  Combined mitoxantrone and anti-TGFβ treatment with PD-1 blockade enhances antitumor immunity by remodelling the tumor immune landscape in neuroblastoma , 2022, Journal of Experimental & Clinical Cancer Research.

[2]  P. Hofman,et al.  PD-1/PD-L1 inhibitors in treatment-naïve, advanced non-small cell lung cancer patients with < 1% PD-L1 expression: a meta-analysis of randomized controlled trials , 2022, Journal of Cancer Research and Clinical Oncology.

[3]  Zhonglin Wang,et al.  Primary and Acquired Resistance against Immune Check Inhibitors in Non-Small Cell Lung Cancer , 2022, Cancers.

[4]  Laura F. Dagley,et al.  TGF-β and CIS inhibition overcomes NK cell suppression to restore anti-tumor immunity. , 2022, Cancer immunology research.

[5]  R. M. Simpson,et al.  CCL5 production in lung cancer cells leads to an altered immune microenvironment and promotes tumor development , 2021, Oncoimmunology.

[6]  Xueda Hu,et al.  Temporal single-cell tracing reveals clonal revival and expansion of precursor exhausted T cells during anti-PD-1 therapy in lung cancer , 2021, Nature Cancer.

[7]  G. Coukos,et al.  Identification of tumor antigens with immunopeptidomics , 2021, Nature Biotechnology.

[8]  Kwok-Kin Wong,et al.  Combined Inhibition of SHP2 and CXCR1/2 Promotes Antitumor T-cell Response in NSCLC , 2021, bioRxiv.

[9]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[10]  L. Tao,et al.  PD-1 blockade improves the anti-tumor potency of exhausted CD3+CD56+ NKT-like cells in patients with primary hepatocellular carcinoma , 2021, Oncoimmunology.

[11]  A. Anichini,et al.  Immune Escape Mechanisms in Non Small Cell Lung Cancer , 2020, Cancers.

[12]  S. Y. Kim,et al.  Update 2020: Management of Non-Small Cell Lung Cancer , 2020, Lung.

[13]  Michael G. Constantinides,et al.  Dissecting the NK Cell Population in Hematological Cancers Confirms the Presence of Tumor Cells and Their Impact on NK Population Function , 2020, Vaccines.

[14]  Y. Jing,et al.  Baseline immunity and impact of chemotherapy on immune microenvironment in cervical cancer , 2020, British Journal of Cancer.

[15]  B. Shi,et al.  Olaparib Suppresses MDSC Recruitment via SDF1α/CXCR4 Axis to Improve the Anti-tumor Efficacy of CAR-T Cells on Breast Cancer in Mice. , 2020, Molecular therapy : the journal of the American Society of Gene Therapy.

[16]  A. Baccarelli,et al.  Outdoor air pollution and cancer: An overview of the current evidence and public health recommendations , 2020, CA: a cancer journal for clinicians.

[17]  C. Klersy,et al.  Reduced Efficacy of Biological Drugs in Psoriatic Patients with HLA-A Bw4-80I KIR Ligands , 2020, Molecular Diagnosis & Therapy.

[18]  T. Jiang,et al.  Pan-cancer analysis of KEAP1 mutations as biomarkers for immunotherapy outcomes. , 2020, Annals of translational medicine.

[19]  Guang Li,et al.  Resistance Mechanism of PD-1/PD-L1 Blockade in the Cancer-Immunity Cycle , 2020, OncoTargets and therapy.

[20]  G. Botti,et al.  Targeting CXCR4 potentiates anti-PD-1 efficacy modifying the tumor microenvironment and inhibiting neoplastic PD-1 , 2019, Journal of Experimental & Clinical Cancer Research.

[21]  A. Barla,et al.  Different Features of Tumor-Associated NK Cells in Patients With Low-Grade or High-Grade Peritoneal Carcinomatosis , 2019, Front. Immunol..

[22]  M. Ahn,et al.  Five-Year Overall Survival for Patients With Advanced Non‒Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  Jianying Zhou,et al.  Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial , 2019, The Lancet.

[24]  M. Socinski,et al.  Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial. , 2019, The Lancet. Respiratory medicine.

[25]  É. Vivier,et al.  Targeting natural killer cells in solid tumors , 2019, Cellular & Molecular Immunology.

[26]  D. Morris,et al.  Immune checkpoint inhibitors and non-small-cell lung cancer management: 2018 update. , 2019, Immunotherapy.

[27]  A. Tafreshi,et al.  Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  A. Butte,et al.  Reference-based analysis of lung single-cell sequencing reveals a transitional profibrotic macrophage , 2018, Nature Immunology.

[29]  Michael J. T. Stubbington,et al.  Single-cell reconstruction of the early maternal–fetal interface in humans , 2018, Nature.

[30]  Xueda Hu,et al.  Lineage tracking reveals dynamic relationships of T cells in colorectal cancer , 2018, Nature.

[31]  J. Borst,et al.  CD4+ T cell help in cancer immunology and immunotherapy , 2018, Nature Reviews Immunology.

[32]  Zev J. Gartner,et al.  DoubletFinder: Doublet detection in single-cell RNA sequencing data using artificial nearest neighbors , 2018, bioRxiv.

[33]  S. Asthana,et al.  A natural killer–dendritic cell axis defines checkpoint therapy–responsive tumor microenvironments , 2018, Nature Medicine.

[34]  S. Novello,et al.  Pembrolizumab plus Chemotherapy in Metastatic Non–Small‐Cell Lung Cancer , 2018, The New England journal of medicine.

[35]  D. Noonan,et al.  Contribution to Tumor Angiogenesis From Innate Immune Cells Within the Tumor Microenvironment: Implications for Immunotherapy , 2018, Front. Immunol..

[36]  Paul Hoffman,et al.  Integrating single-cell transcriptomic data across different conditions, technologies, and species , 2018, Nature Biotechnology.

[37]  Eun Ho Kim,et al.  Knockdown of end-binding protein 1 induces apoptosis in radioresistant A549 lung cancer cells via p38 kinase-dependent COX-2 upregulation. , 2018, Oncology Report.

[38]  Deborah S. Barkauskas,et al.  CCL3 augments tumor rejection and enhances CD8+ T cell infiltration through NK and CD103+ dendritic cell recruitment via IFNγ , 2018, Oncoimmunology.

[39]  E. Sahai,et al.  NK Cells Stimulate Recruitment of cDC1 into the Tumor Microenvironment Promoting Cancer Immune Control , 2018, Cell.

[40]  P. Jänne,et al.  TGF&bgr; pathway inhibition in the treatment of non‐small cell lung cancer , 2017, Pharmacology & therapeutics.

[41]  L. Moretta,et al.  Markers and function of human NK cells in normal and pathological conditions , 2017, Cytometry. Part B, Clinical cytometry.

[42]  E. Barreiro,et al.  Systemic and Tumor Th1 and Th2 Inflammatory Profile and Macrophages in Lung Cancer: Influence of Underlying Chronic Respiratory Disease , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[43]  M. Joerger,et al.  The IL-17-Th1/Th17 pathway: an attractive target for lung cancer therapy? , 2016, Expert opinion on therapeutic targets.

[44]  C. Kurts,et al.  The Role of Invariant Natural Killer T Cells in Dendritic Cell Licensing, Cross-Priming, and Memory CD8+ T Cell Generation , 2015, Front. Immunol..

[45]  J. Chiang,et al.  Tumor-Derived Chemokine CCL5 Enhances TGF- b – Mediated Killing of CD8 þ T Cells in Colon Cancer by T-Regulatory Cells , 2012 .

[46]  P. Validire,et al.  Profound coordinated alterations of intratumoral NK cell phenotype and function in lung carcinoma. , 2011, Cancer research.

[47]  M. Caligiuri,et al.  Innate or Adaptive Immunity? The Example of Natural Killer Cells , 2011, Science.